LARGE MOLECULE CAPACITY UPDATES

11:48

Northway Biotech Capacity Update April 2025: Large Molecule Development

Detra Glinatsis, Vice President of Business Development, presents the advanced capabilities, strategic growth, and expanding capacity of Northway Biotech, a global biologics CDMO.

21:59

Abzena Capacity Update April 2025: Large Molecule Development

See first-hand how AbZelectPRO™, an evolved approach to cell line development, can simplify selection, enhance stability, and de-risk your program for faster regulatory approval.

22:07

Curia Capacity Update April 2025: Large Molecule Development

Site head Bill Hermans showcases our facility's specialized capabilities in Hopkinton, Massachusetts, and shares how our team serves as a true scientific partner to clients.

20:07

Cytovance Biologics Capacity Update April 2025: Large Molecule Development

Speed up your program with end-to-end microbial and mammalian biologics development and manufacturing expertise — spanning everything from biosimilars to vaccines.

18:25

Novartis Capacity Update April 2025: Large Molecule Development

Experience a global network of expertise and proven manufacturing capabilities that can help accelerate your clinical and commercial drug substance programs.

17:57

Samsung Biologics Capacity Update April 2025: Large Molecule Development

Leveraging advanced technology, expertise, and flexible capacity, clients can reduce development time and costs while ensuring a smooth transition from clinical to commercial manufacturing.

18:41

Boehringer Ingelheim Capacity Update April 2025: Large Molecule Development

Explore how world-class contract manufacturing expertise and global capabilities can help accelerate your biologic from development to commercial success.

20:51

Catalent Capacity Update April 2025: Large Molecule Development

By leveraging our proprietary non-viral gene insertion technology, GPEx® Lightning ensures rapid development timelines and high-yield production, making it an ideal solution for complex biologics.

24:39

FUJIFILM Diosynth Biotechnologies Capacity Update April 2025: Large Molecule Development

Associate Director kojoX and Technology Development, Rasmus Petersen, presents a high-level overview of FDB’s capabilities, its global facilities network, and capacity updates for BIOLOGICS.

16:35

Northway Biotech Capacity Update January 2025: Large Molecule Development

Over the past 20 years, we have completed more than 175 successful projects around the globe, showcasing our commitment to quality and customer satisfaction.

20:21

Mabion Capacity Update January 2025: Large Molecule Development

Go on a virtual tour of our GMP-certified facility, where we uphold our expanded capabilities for large molecule development to the highest standards for clinical and commercial manufacturing.

21:08

KBI Biopharma Capacity Update January 2025: Large Molecule Development

Follow along as Derek Ryan, Sr. Director of Analytical Development, showcases our high-throughput technology and digital tools for process understanding and optimizing decision-making.

23:02

Cytovance Biologics Capacity Update January 2025: Large Molecule Development

Join Rose Rhomberg, Senior Business Development Director, as she showcases Cytovance’s microbial and mammalian capabilities, along with our available manufacturing capacity.

18:10

Catalent Capacity Update January 2025: Large Molecule Development

Learn how our expertise and advanced capabilities provide customized analytical solutions that ensure quality, precision, and regulatory compliance for your biotherapeutics.

14:29

Northway Biotech Capacity Update October 2024: Large Molecule Drug Substance

We have the capabilities, competitive advantages, and capacity to onboard new projects across two facilities: Waltham, MA, operational since 2020, and Vilnius, Lithuania, established in 2004.

22:00

Cytovance Biologics Capacity Update October 2024: Large Molecule Drug Substance

Senior Business Development Director Rose Rhomberg presents an in-depth look at Cytovance’s capabilities and highlights the available capacity designed to accelerate your goals.

18:39

Novartis Contract Manufacturing Capacity Update October 2024: Large Molecule Drug Substance

Gain valuable insights into our mammalian development services, manufacturing solutions, upcoming capacity availability, as well as updates on expansion timelines for external clients.

12:04

Pfizer CentreOne Capacity Update October 2024: Large Molecule Drug Substance

See how our specialized manufacturing site in Sanford, NC — backed by over 35 years of expertise in mAb production — can expedite the delivery of your groundbreaking therapies to patients.

22:29

Resilience Capacity Update October 2024: Large Molecule Drug Substance

Business Head of Biologics and Vaccines Evan Pasenello shares how Resilience’s innovative platforms and specialized expertise can effectively support your development and manufacturing programs.

22:52

Boehringer Ingelheim BioXcellence™ Capacity Update October 2024: Large Molecule Drug Substance

Explore our global production network, advanced aseptic filling, in-house analytics, and the expertise that has driven 47 biopharmaceuticals to market success.

20:57

FUJIFILM Diosynth Biotechnologies Capacity Update October 2024: Large Molecule Drug Substance

Rasmus Pedersen, Ph.D., outlines strategies to expand large-molecule production capacity to meet the global medicine demand, noting the current gap that leaves 2 billion people without access.

19:15

Samsung Biologics Capacity Update October 2024: Large Molecule Drug Substance

We're poised to be your next growth engine with our commitment to quality, speed, and agility, as we expand our facilities and invest in innovative modalities to meet your large molecule needs.

19:17

Cytovance Capacity Update July 2024: Large Molecule Development

Centrally located in the United States, with a decades-long history in biologics development and manufacturing, Cytovance delivers ingenuity end-to-end to both large pharma and biotech clients alike.

20:31

ATON Bio Capacity Update July 2024: Large Molecule Development

Gain insights into boosting efficiency, fostering innovation, and how integrated capabilities generate value for innovators.

23:02

Mabion Capacity Update July 2024: Large Molecule Development

Explore our new installations in upstream development, bioreactors, and fill-finish. This state of the art EU-GMP facility is staffed by a team of 250 professionals, and capacity is now available.

21:12

Novartis Contract Manufacturing Capacity Update July 2024: Large Molecule Development

Review our capabilities in tech transfer, clinical drug substance, and commercial drug substance manufacturing across our manufacturing network in Singapore, Europe, and the US.

21:11

AbbVie Capacity Update July 2024: Large Molecule Development

Delve into the intricacies of biopharmaceutical manufacturing, focusing on stages such as CLD, fermentation, and purification. We also explore process optimization and scale-up techniques.

13:20

Scorpius Biomanufacturing Capacity Update July 2024: Large Molecule Development

Scorpius' VP of Manufacturing Operations Matt LeClair presents a 3D virtual tour of the process development lab, analytical and QC lab, and the mammalian manufacturing upstream and cell culture suites.

21:16

KBI Biopharma Capacity Update May 2024: Large Molecule Development

Discover how our development and platform-based manufacturing solutions can create an unobstructed path to market for your large molecule pipeline in a dynamic regulatory environment.

21:24

JOINN Biologics Capacity Update May 2024: Large Molecule Development

JOINN Biologics US Inc. is a California-based CDMO that provides our customers with flexible solutions for complex biologics, including ADCs. JOINN Biologics is a combination of "Big Pharma Infrastructure" with 200L and 1000L traditional stainless steel bioreact...

19:46

OUTSOURCED PHARMA CAPACITY UPDATE LARGE MOLECULE VIDEOS